Objective To investigate the efficacy and safety of α-glucosidase inhibitor in combination with DPP-4 inhibitor on type 2 diabetes mellitus. Methods A total of 120 patients with T2DM were randomly divided into two groups :observation group using α-glucosidase inhibitor in combination with DPP-4 inhibitor (n= 60) and control group treated with DPP-4 inhibitor monotherapy (n= 60). All patients were followed up for 16 weeks. Blood glucose and biochemical indices were measured at baseline and after treatment. Adverse events and effect of treatment on C-RP were observed. Results After treatment ,FPG[(9.02 ± 1.11) vs (7.14 ± 1.41) mmol/L] ,2 hPG[(15.28 ± 1.08) vs (9.85 ± 1.59) mmol/L] ,HbA1c[(8.24 ± 1.92)% vs (6.68 ± 1.24)% ] and C-RP level[(8.82 ± 1.71) vs (5.14 ± 1.21) mg/L] were lower in observation group than in control group. Proportion of patients with targeted HbA1c was higher in observation group than in control group [76.67% (46/60) vs 63.33% (38/60)] (P<0.05) . The differences of blood glucose indicators and C-RP level between baseline and after-treatment in both groups were statistically significant (P<0.05). Conclusion α-glucosidase inhibitor in combination with DPP-4 inhibitor has a better effect on T 2DM treatment and C-RP level than DPP-4 inhibitor monotherapy.%目的：探讨α糖苷酶抑制剂与二肽基肽酶-4（DPP-4）抑制剂联合治疗T2DM患者的有效性及安全性。方法将120例T2DM患者随机分为观察组和对照组，各60例。观察组采用α糖苷酶抑制剂与DPP-4抑制剂联合治疗，对照组单独应用DPP-4抑制剂治疗，随访16周，测定治疗前后血糖及生化指标，观察不良反应发生情况及治疗对C-RP的影响。结果治疗后，观察组FPG[（9.02±1.11） vs （7.14±1.41） mmol／L]、2 hPG[（15.28±1.08） vs （9.85±1.59） mmol／L]、HbA1c[（8.24±1.92）％ vs （6.68±1.24）％]及C-RP[（8.82±1.71） vs （5.14±1.21） mg／L]水平降低；观察组 HbA1c的达标率高于对照组[76.67％（46／60） vs 63.33％（38／60）]（P＜0.05）。两组血糖指标和C-RP水平治疗前后差值比较，差异有统计学意义（P＜0.05）。结论α糖苷酶抑制剂与DPP-4抑制剂联合应用与单独应用DPP-4抑制剂相比，治疗T2DM 效果更好，且降低血清C-RP效果更佳。
展开▼
